Superficial Vein Thrombosis (SVT) Treated With Rivaroxaban Versus

Clinical Trial Description

Evaluation of efficacy and safety of 45 days of rivaroxaban 10 mg vs. fondaparinux 2.5 mg in the treatment of superficial vein thrombosis of risk patients for major VTE complications to prove non-inferiority of oral rivaroxaban treatment ;

Study Design

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT04136561` - Novel Strategy to Encourage Early Removal of Central Venous Catheters	N/A
Completed	`NCT01501175` - Incidence of Superficial Vein Thrombosis	N/A
Completed	`NCT05001776` - Endovenous Laser Ablation in Acute Thrombophlebitis of the Varicose Great Saphenous Vein	Phase 4
Completed	`NCT02699151` - INvestigating SIGnificant Health TrendS in the Management of Superficial Vein Thrombosis

See also

Status

Clinical Trial

Phase

Withdrawn

NCT04136561 - Novel Strategy to Encourage Early Removal of Central Venous Catheters

N/A

Completed

NCT01501175 - Incidence of Superficial Vein Thrombosis

N/A

Completed

NCT05001776 - Endovenous Laser Ablation in Acute Thrombophlebitis of the Varicose Great Saphenous Vein

Phase 4

Completed

NCT02699151 - INvestigating SIGnificant Health TrendS in the Management of Superficial Vein Thrombosis

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT01499953
Study type	Interventional
Source	GWT-TUD GmbH
Contact
Status	Completed
Phase	Phase 3
Start date	April 2012
Completion date	May 2016

Superficial Vein Thrombosis (SVT) Treated With Rivaroxaban Versus Fondaparinux

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms